enitociclib   Click here for help

GtoPdb Ligand ID: 11686

Synonyms: BAY 1251152 | BAY-1251152 | BAY1251152 | VIP-152 | VIP152
Compound class: Synthetic organic
Comment: VIP152 is a clinical stage CDK9 inhibitor [1]. Once weekly i.v. administration is effective in rodent xenograft models, without negative safety or tolerability issues. We were able to match the chemical structure of VIP152 to the INN enitociclib that was included in the WHO proposed INN list 126 (Jan 2022).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 96.34
Molecular weight 404.11
XLogP 4.44
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(F)ccc1c1cc(ncc1F)Nc1nccc(c1)C[S@](=O)(=N)C
Isomeric SMILES COc1cc(F)ccc1c1cc(Nc2cc(C[S@@](=N)(=O)C)ccn2)ncc1F
InChI InChI=1S/C19H18F2N4O2S/c1-27-17-8-13(20)3-4-14(17)15-9-19(24-10-16(15)21)25-18-7-12(5-6-23-18)11-28(2,22)26/h3-10,22H,11H2,1-2H3,(H,23,24,25)/t28-/m0/s1
InChI Key YZCUMZWULWOUMD-NDEPHWFRSA-N
No information available.
Summary of Clinical Use Click here for help
VIP152 has been advanced to clinical evaluation, ultimately to determine antitumour activity.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02635672 Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer Phase 1 Interventional Vincerx Pharma, Inc.
NCT04978779 A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome Phase 1 Interventional Vincerx Pharma, Inc.